Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease. by Almers, Lucy M et al.
UC Davis
UC Davis Previously Published Works
Title
Adiponectin May Modify the Risk of Barrett's Esophagus in Patients With 
Gastroesophageal Reflux Disease.
Permalink
https://escholarship.org/uc/item/66z75611
Journal
Clinical gastroenterology and hepatology : the official clinical practice journal of the 
American Gastroenterological Association, 13(13)
ISSN
1542-3565
Authors
Almers, Lucy M
Graham, James E
Havel, Peter J
et al.
Publication Date
2015-12-01
DOI
10.1016/j.cgh.2015.01.009
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Clinical Gastroenterology and Hepatology 2015;13:2256–2264ALIMENTARY TRACTAdiponectin May Modify the Risk of Barrett’s Esophagus in
Patients With Gastroesophageal Reflux DiseaseLucy M. Almers,* James E. Graham,‡,§ Peter J. Havel,‡,§ and Douglas A. Corley*
*Division of Research, Kaiser Permanente, Oakland, California; ‡Department of Molecular Biosciences, School of Veterinary
Medicine, §Department of Nutrition, University of California, Davis, CaliforniaBACKGROUND & AIMS: Abdominal obesity and increasing body mass index are risk factors for esophageal adenocar-
cinoma and its main precursor, Barrett’s esophagus; however, there are no known biological
mechanisms for these associations or regarding why only some patients with gastroesophageal
reﬂux disease develop Barrett’s esophagus. We evaluated the association between Barrett’s
esophagus and multimers of an adipose-associated hormone, adiponectin.METHODS: We conducted a case-control study evaluating the associations between adiponectin (total,
high-molecular-weight, and low-/medium-molecular-weight) and Barrett’s esophagus within
the Kaiser Permanente Northern California population. Patients with a new diagnosis of Bar-
rett’s esophagus (cases) were matched to patients with gastroesophageal reﬂux disease (GERD)
without Barrett’s esophagus and to population controls.RESULTS: Complete serologic and epidemiologic data were available for 284 cases, 294 GERD controls,
and 285 population controls. Increasing adiponectin levels were a risk factor for Barrett’s
esophagus among patients with GERD (total adiponectin fourth vs ﬁrst quartile odds ratio
[OR], 1.96; 95% conﬁdence interval [CI], 1.17–3.27; high-molecular-weight adiponectin
OR, 1.65; 95% CI, 1.00-2.73; low-/medium-molecular-weight adiponectin OR, 2.18; 95% CI,
1.33–3.56), but not compared with population controls. The associations were signiﬁcantly
stronger among patients reporting frequent GERD symptoms and among smokers (P values
interaction < .01).CONCLUSIONS: Adiponectin levels are associated positively with the risk of Barrett’s esophagus among patients
with GERD and among smokers, but not among population controls without GERD symptoms.
Higher adiponectin concentrations either independently may contribute to the aberrant healing
of esophageal injury into Barrett’s esophagus or be a marker for other factors.Keywords: Esophageal Adenocarcinoma; Adiponectin; BMI; Barrett’s Esophagus; Adipokines.Abbreviations used in this paper: BMI, body mass index; CI, conﬁdence
interval; GERD, gastroesophageal reﬂux disease; KPNC, Kaiser Perma-
nente Northern California; OR, odds ratio.
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The incidence of esophageal adenocarcinoma hasincreased more than 500% in the United States
over the past 3 decades; it accounts for more than 2% of
male cancer deaths.1,2 Barrett’s esophagus likely repre-
sents a metaplastic healing response to esophageal
injury, typically from gastroesophageal reﬂux disease
(GERD).3 Its presence increases the risk for esophageal
adenocarcinoma by 30- to 40-fold.4 Barrett’s esophagus
is associated with obesity, especially abdominal
obesity,5,6 although the biological links between obesity,
Barrett’s esophagus, and cancer are unclear.5,7,8
Circulating adiponectin, an adiposity-associated hor-
mone, is associated inversely with adiposity and insulinresistance9,10; it may represent a mechanistic link be-
tween Barrett’s esophagus and obesity.11–13 Animal
models suggest that adiponectin inﬂuences the healing
response of the gastrointestinal mucosa.14 Mice lacking
adiponectin, for example, had more ethanol-induced
gastric injury than normal mice, whereas adiponectin
administration improved gastric mucosal repair.14 Adi-
ponectin is also a potentially modiﬁable factor, given that
adiponectin agonists and homologs currently are being
studied as potential therapeutic agents.15,16
December 2015 Adiponectin and Barrett’s Esophagus 2257We evaluated the associations between circulating
adiponectin subtypes and the risk of Barrett’s esophagus
using 2 control groups: patients diagnosed with GERD
and population controls.
Methods
Study Design and Population
We conducted a nested case-control study within
Kaiser Permanente Northern California (KPNC).17 Pa-
tients were 18 to 79 years of age and members contin-
uously for 2 or more years before their index date. The
design and analyses were approved by the KPNC insti-
tutional review board (September 2002).
Case Deﬁnition
Cases were eligible KPNC members with a new
diagnosis of Barrett’s esophagus between October 2002
and September 2005, identiﬁed using the International
Classiﬁcation of Diseases, 9th revision code 530.2,
deﬁned at KPNC as “Barrett’s esophagitis.” A gastroen-
terologist (D.A.C.) reviewed the endoscopy and pathology
records. Patients were included if there was a visible
length of columnar-type epithelium proximal to the
gastroesophageal junction/gastric folds, and an esopha-
geal biopsy specimen showed specialized intestinal
epithelium18 (after pathologist slide review). Patients
were excluded if they had only gastric-type or columnar
metaplasia without intestinal metaplasia, lacked an
esophageal biopsy specimen or had biopsy specimens
only of a mildly irregular squamocolumnar junction, had
a prior diagnosis of Barrett’s esophagus, or had esoph-
ageal cancer (dysplasia was included). The index date
was the date of Barrett’s esophagus diagnosis.
Gastroesophageal Reﬂux Disease Controls
GERD control members had all of the following before
entry: a GERD-related International Classiﬁcation of
Diseases, 9th revision code (530.11 [reﬂux esophagitis]
or 530.81 [gastroesophageal reﬂux]), a prescription for
90 days’ or more use of a histamine-2–receptor antago-
nist or a proton pump inhibitor in the previous year, no
prior diagnosis of Barrett’s esophagus, and a recent
esophagogastroduodenoscopy that did not show esoph-
ageal columnar metaplasia of any type.
Population Controls
Population controls were selected randomly from the
at-risk (no prior Barrett’s esophagus diagnosis) KPNC
membership, using risk set sampling.19 The index date
for controls was the midpoint of each 2- to 3-month case
selection interval. The population and GERD controls
were frequency matched to cases by sex, age at indexdate (5-year age groups), and geographic region (medical
facility).
Exposure Measurements
Serum samples were stored at 80C because adipo-
nectin is stable when frozen.20,21 Concentrations were
assayed in duplicate, using mixed cases and controls, by
researchers experienced with adiponectin analysis
(P.J.H.). High-molecular-weight adiponectin measure-
ments used an enzyme-linked immunosorbent assay
(ALPCO, Salem, NH), total measurements used a radio-
immunoassay (Millipore, Billerica, MA). We compared
same-sample interassay values and adjusted for differ-
enceswith a conversion factor. The adiponectin ratio is the
high-molecular-weight adiponectin/total adiponectin.
All subjects completed the following: an in-person
interview of GERD symptoms and use of medications,
tobacco, and alcohol (all for the year before the index
date and longer exposures); a validated food frequency
questionnaire (Block et al,22 full-length questionnaire);
and measurements of height, weight, waist (obtained at
the iliac crest while standing) and thigh circumferences,
and serum Helicobacter pylori serum antibody status.
Examinations used trained interviewers, most commonly
at the subject’s home. GERD assessments used a vali-
dated symptom questionnaire23 for heartburn or acid
regurgitation.Statistical Analysis
The study used standard techniques for unpaired
case-control studies, including unconditional logistic
regression.19,24 Comparisons of proportions used bino-
mial distribution (Stata version 10.1; Stata Corp, College
Station, TX). Continuous adiponectin measures used log-
transformed values. Quartiles used distributions among
the population controls and sex-speciﬁc quartiles for sex-
stratiﬁed analyses.
We evaluated the following as potential confounders:
education (<7, 7–9, 10–11, 12þ y); smoking status (20
vs < 20 lifetime-packs)25; alcohol (ever vs never drank
alcohol); total daily calories, antioxidants (vitamins A, C,
and E; carotene; and selenium), fat intake, fruits, vege-
tables, and iron; multivitamins; GERD symptom fre-
quency (<weekly vs weekly); a comorbidity index26,27;
H pylori serum antibody status; aspirin and nonsteroidal
anti-inﬂammatory medication use; body mass index
(BMI); waist circumference; and race. We evaluated for
effect modiﬁcation by race, sex, smoking, and GERD
symptom frequency using cross-product terms in the
crude logistic regression model and stratum-speciﬁc
odds ratios (ORs).28
A potentially confounding variable was retained if it
changed the main effect OR by 10% or more for at least 2
adiponectin variables (total adiponectin, high-molecular-
weight adiponectin, low-/medium-molecular-weight
Table 1. Characteristics of Study Groups
Cases
Population
controls
GERD
controls
Subjects, n (%) 310 (100.0) 305 (100.0) 308 (100.0)
Mean age, y (SD) 62 (10.7) 62 (10.2) 62 (10.7)
Age, n (%)
20–39 y 7 (2.3) 9 (3.0) 11 (3.6)
40–59 y 118 (38.1) 102 (33.4) 111 (36.0)
60–79 y 185 (59.7) 194 (63.6) 186 (60.4)
Race, n (%)
Non-Hispanic white 271 (87.4) 259 (84.9) 248 (80.5)
Black 4 (1.3) 16 (5.2) 20 (6.5)
Hispanic 24 (7.7) 12 (3.9) 20 (6.5)
Asian 3 (1.0) 8 (2.6) 7 (2.3)
Other 8 (2.6) 10 (3.3) 13 (4.2)
Sex, n (%)
Male 227 (73.2) 208 (68.2) 212 (68.8)
Smoking status (ever
smoked), n (%)
206 (66.5) 170 (55.7) 183 (59.4)
GERD score,a n (%)
Any GERD
symptoms
289 (93.2) 185 (60.7) 289 (93.8)
At least weekly 248 (80.0) 86 (28.2) 226 (73.4)
Mean current weight
(SD), kg
86.9 (21.4) 87.0 (18.8) 83.8 (16.8)
Mean waist (SD), cm 100.7 (14.9) 99.1 (17.5) 97.2 (14.3)
BMI,b mean (SD) 29.4 (6.1) 29.4 (5.8) 28.8 (5.2)
BMI,b n (%)
Underweight 5 (1.6) 2 (0.7) 4 (1.3)
Normal 60 (19.4) 68 (22.3) 63 (20.5)
Overweight 122 (39.4) 116 (38.0) 134 (43.5)
Obese 123 (39.7) 119 (39.0) 107 (34.7)
Adiponectin multimers,
mean (SD)
Total, mg/mL 12.8 (7.7) 12.1 (6.7) 11.7 (6.8)
High molecular weight
(SD), mg/mL
3.4 (2.9) 3.2 (2.6) 3.1 (2.7)
Low þ medium
molecular weight
(SD), mg/mL
4.3 (2.0) 4.1 (1.8) 3.9 (1.7)
Ratio: high molecular
weight/total (SD)
0.40 (0.1) 0.40 (0.1) 0.40 (0.1)
aGERD score represents the patient’s report of frequency of GERD symptoms,
which is not a criterion for GERD diagnosis. Thus, the category of “Any GERD
symptoms” will not be 100% among GERD control group subjects.
bBMI categories were based on international standards as presented by the
World Health Organization Global Database on Body Mass Index.
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therefore were adjusted for waist circumference, race,
and the main frequency-matched variables (sex and age).
The covariates were evaluated separately for both
population-based controls and GERD controls. The vari-
ables that changed the OR by more than 10% were
similar for both comparison groups, thus the same con-
founding structure was used in the model for both
comparisons.
Results
Patient Characteristics
Complete data were available for 96.8% (n ¼ 923) of
all interviewed subjects (Table 1). Thirty persons were
excluded because of missing values for the following:
waist (n ¼ 4), serum availability for adiponectin mea-
surement (n ¼ 25), and race/ethnicity (n ¼ 1). GERD
controls had a lower mean weight (184.7 lb) than cases
(191.5 lb) or population controls (191.8 lb). Cases were
more likely to have at least weekly GERD symptoms
(80.0%) (vs GERD controls [73.4%] or population con-
trols [28.2%]) and to be non-Hispanic whites (87.4%) (vs
population controls [84.9%] or GERD controls [80.5%]).
Cases Versus Gastroesophageal Reﬂux
Disease Controls
Participants in the fourth (vs ﬁrst) quartile of total
and lowþmedium-weight adiponectin were twice as
likely to have Barrett’s esophagus (total adiponectin OR,
1.96; 95% conﬁdence interval [CI], 1.17–3.27;
lowþmedium-weight OR, 2.18; 95% CI, 1.33–3.56)
(Table 2, Figure 1). Similarly, participants in the fourth
quartile of high-molecular-weight adiponectin were
more likely to have Barrett’s esophagus (OR, 1.65; 95%
CI, 1.00–2.73) (Table 2, Figure 1). Similar signiﬁcant
associations were seen for continuous measures of total,
high-molecular-weight, and low-/medium-molecular-
weight adiponectin (Table 2).
Cases Versus Population Controls
Increasing adiponectin levels were associated with
Barrett’s esophagus among population controls with
GERD symptoms, but not among population controls
overall or population controls with minimal or no
GERD symptoms (P value interaction total adiponectin,
P < .001) (Tables 2 and 3, Figure 2). Continuous
measures of total and high-molecular-weight adipo-
nectin were associated positively with Barrett’s
esophagus among cases/population controls with
frequent GERD symptoms (weekly), comparable with
subjects in the larger physician-deﬁned GERD control
group (total adiponectin: OR, 1.68; 95% CI, 1.01–2.80;
high-molecular-weight adiponectin: OR, 1.50; 95% CI,1.04–2.15) (Table 3). Analyses by quartile had overall
similar directions, although with wider conﬁdence
intervals.
Smoking
Total adiponectin. For comparisons with GERD con-
trols, there were positive associations between total,
high-molecular-weight, and low-/medium-molecular-
weight adiponectin and Barrett’s esophagus among ever
smokers (total adiponectin: OR, 1.83; 95% CI, 1.20–2.78;
high-molecular-weight adiponectin: OR, 1.46; 95% CI,
1.09–1.97; low-/medium-molecular-weight adiponectin:
OR, 2.11; 95% CI, 1.27–3.49), but not among never
Table 2. Adiponectin and Barrett’s Esophagus: Cases Versus Population and GERD Control Groups
Counts
Cases vs population
controls Cases vs GERD controls
Cases
Population
controls
GERD
controls Adjusted OR 95% CI Adjusted OR 95% CI
Total adiponectin
Quartiles, mg/mL
<7.35 80 77 81 Ref Ref
7.36–10.55 63 76 88 0.83 (0.53–1.33) 0.79 (0.50–1.25)
10.56–15.41 82 76 75 1.13 (0.72–1.77) 1.33 (0.84–2.11)
>12.46 85 76 64 1.36 (0.83–2.23) 1.96 (1.17–3.27)
Continuous, log-transformed 310 305 308 1.36 (0.97–1.89) 1.66 (1.19–2.32)
Adiponectin high MW
Quartiles, mg/mL
<1.46 82 77 89 Ref Ref
1.46–2.53 74 76 77 0.95 (0.61–1.50) 1.16 (0.74–1.83)
2.54–4.00 69 76 66 0.92 (0.58–1.45) 1.32 (0.82–2.12)
>4.02 85 76 76 1.32 (0.80–2.17) 1.65 (1.00–2.73)
Continuous, log-transformed 310 305 308 1.20 (0.96–1.51) 1.33 (1.05–1.68)
Adiponectin low þ medium MW
Quartiles, mg/mL
<2.75 72 77 87 Ref Ref
2.75–3.80 78 76 76 1.15 (0.73–1.81) 1.33 (0.84–2.10)
3.80–5.07 69 76 77 1.06 (0.66–1.69) 1.25 (0.79–1.99)
>5.07 91 76 68 1.56 (0.97–2.53) 2.18 (1.33–3.56)
Continuous, log-transformed 310 305 308 1.44 (0.98–2.11) 1.88 (1.28–2.78)
Adiponectin ratio high MW/total
Quartiles
<0.32 86 77 67 Ref Ref
0.32–0.39 67 76 93 0.81 (0.51–1.27) 0.58 (0.36–0.91)
0.39–0.47 82 76 70 1.03 (0.66–1.63) 0.92 (0.57–1.48)
>0.47 75 76 78 0.98 (0.61–1.57) 0.82 (0.50–1.34)
Continuous, log-transformed 310 305 308 1.22 (0.71–2.09) 1.19 (0.68–2.08)
NOTE. Adjusted OR was adjusted for sex, age, race/ethnicity, and waist circumference. Quartiles were based on the population control groups.
MW, molecular weight.
December 2015 Adiponectin and Barrett’s Esophagus 2259smokers (Supplementary Table 1, Figure 3). The associ-
ations were strongest among current smokers, although
with limited power to evaluate current smokers
(Supplementary Table 1, Figure 3). Similar positive as-
sociations between total, high-molecular-weight, and
medium-molecular-weight adiponectin and Barrett’s
esophagus also were seen in the case vs population
control comparison group for ever smokers, but not for
never smokers (data not shown).
Stratiﬁcations by Sex
The associations between total adiponectin levels and
Barrett’s esophagus were somewhat stronger among
women than among men, among GERD controls
(continuous total adiponectin women: OR, 2.27; 95% CI,
1.15–4.47; men: OR, 1.50; 95% CI, 1.02–2.22; P value
interaction, .10) (Supplementary Table 2). Low-/me-
dium-molecular-weight adiponectin had signiﬁcant as-
sociations or strong trends with the risk of Barrett’s
esophagus among both men and women, whereas high-
molecular-weight adiponectin showed signiﬁcant asso-
ciations only among women (Supplementary Table 2).For cases vs population controls, women showed sig-
niﬁcant associations for total adiponectin, high-
molecular-weight adiponectin, and adiponectin ratio,
but not for low-/medium-molecular-weight adiponectin
(data not shown).
Stratiﬁcations by Body Mass Index
The nonsigniﬁcant trends for associations between
adiponectin and Barrett’s esophagus were stronger
among persons with a normal BMI (eg, log-transformed
total adiponectin, continuous value OR, 2.22; 95%
CI, 0.98–5.04), than among overweight (OR, 1.32;
95% CI, 0.76–2.30) or obese persons (OR, 1.15;
95% CI, 0.68–1.94). Similar patterns were seen for
high- and lowþmedium-weight adiponectin multimers
(Supplementary Table 3).
Inﬂuence of Proton Pump Inhibitors
Among the population controls, mean adiponectin
levels were similar between PPI users vs nonusers
(mean, 11.88 vs 12.99, respectively; P ¼ .24). A logistic
Figure 1. Adiponectin and
Barrett’s esophagus: cases
vs GERD controls. Odds
ratios (black circles) and
95% conﬁdence intervals
(black bars) for adiponectin
quartiles adjusted for sex,
age, race/ethnicity, and
waist circumference. Q,
quartile.
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no signiﬁcant association between adiponectin levels and
PPI use (data not shown).
Evaluation of Assumptions
We evaluated previously reported associations for
adiponectin using the population controls.29–32 As ex-
pected, the mean adiponectin levels decreased with
increasing BMI (P < .0001), were lower among men
(P < .001), and increased with age (P < .0001). Unlike
some prior reports, it was not correlated with smoking
status (ever vs never).32
If adiponectin mediates the association between waist
circumference and Barrett’s esophagus, we would expect
the association between adiponectin and Barrett’s
esophagus to diminish after controlling for obesity. On
the contrary, for cases vs GERD controls, the association
for low-/medium-molecular-weight adiponectin actually
strengthened after adjusting for BMI (unadjusted OR,
1.45; 95% CI, 1.01–2.08; adjusted OR, 1.55; 95% CI,
1.07–2.25), and for both BMI and waist circumference
(OR, 1.80; 95% CI, 1.22–2.65).Discussion
These results suggest that increasing serum con-
centrations of total adiponectin, high-molecular-weight
adiponectin, and low-/medium-molecular-weight adipo-
nectin are associated with an increased risk of Barrett’s
esophagus among people with a physician-assignedGERD diagnosis, population controls with frequent self-
reported GERD symptoms and smokers, but not among
persons without GERD symptoms and nonsmokers.
The current study adds knowledge regarding the as-
sociations between adiponectin and the body’s response
to injury. Barrett’s esophagus is thought to result from an
aberrant healing response to esophageal injury, most
commonly gastroesophageal reﬂux. A positive associa-
tion between adiponectin and esophageal healing is
biologically plausible; animal models show it is associ-
ated strongly with gastrointestinal mucosal healing after
caustic injury.14 Adiponectin may modify pathways for
cell injury and repair, such as the nitric oxide and
interleukin pathways.11,12 Smoking also is associated
with both the risk of esophagitis and the risk of Barrett’s
esophagus independent of GERD.33 Two potential ex-
planations for our ﬁndings include the following: higher
adiponectin levels may increase the risk of a metaplastic
healing response (ie, Barrett’s esophagus) in response to
GERD-induced injury and smoking; or higher adiponectin
levels may increase the risk of esophagitis, which is
associated with both smoking and GERD. The second
explanation is less likely given that adiponectin was not
associated independently with either smoking or GERD
symptoms among our population controls (data not
shown).
Adiponectin’s associations with mucosal healing may
differ from its other roles with carcinogenesis. Adipo-
nectin levels have been associated inversely with the
risk of prostate, colon, gastric, endometrial, and breast
cancers.34–38 Adiponectin inhibits leptin-induced cell
growth,39 suggesting that high serum concentrations
Table 3. Associations of Adiponectin and Barrett’s Esophagus: Stratiﬁed by GERD Symptom Frequency for Cases Versus
Population Controls
Less than weeklya At least weeklyb
Cases Controlsc Adjusted OR 95% CI Cases Controls Adjusted OR 95% CI
Total adiponectin
interaction term <0.001
Quartiles, mg/mL
<7.35 19 51 Ref 61 26 Ref
7.36–10.55 14 51 0.67 (0.29–1.55) 49 25 0.83 (0.42–1.64)
10.56–15.41 9 60 0.39 (0.16–0.99) 73 15 2.11 (1.00–4.45)
>15.46 20 56 1.24 (0.52–2.95) 65 20 1.56 (0.72–3.37)
Continuous, log-transformed 62 218 1.16 (0.62–2.20) 248 86 1.68 (1.01–2.80)
Adiponectin high MW
interaction term <0.001
Quartiles, mg/mL
<1.46 20 48 Ref 62 29 Ref
1.46–2.53 14 53 0.55 (0.24–1.27) 60 23 1.18 (0.60–2.32)
2.54–4.00 12 61 0.42 (0.18–0.99) 57 15 1.72 (0.82–3.63)
>4.02 16 56 0.84 (0.35–2.04) 69 19 1.95 (0.89–4.29)
Continuous, log-transformed 62 218 0.98 (0.64–1.51) 248 86 1.50 (1.04–2.15)
Adiponectin low þ medium MW
interaction term <0.001
Quartiles, mg/mL
<2.75 16 56 Ref 56 21 Ref
2.75–3.80 16 52 1.02 (0.45–2.33) 62 24 0.91 (0.45–1.85)
3.80–5.07 12 55 0.80 (0.33–1.93) 57 20 1.16 (0.55–2.43)
>5.07 18 55 1.57 (0.66–3.72) 73 21 1.33 (0.62–2.84)
Continuous, log-transformed 62 218 1.52 (0.72–3.21) 248 86 1.56 (0.87–2.80)
Adiponectin ratio high MW/total
interaction term <0.001
Quartiles
<0.32 19 48 Ref 67 29 Ref
0.32–0.39 12 52 0.56 (0.24–1.33) 55 24 0.95 (0.48–1.86)
0.39–0.47 16 60 0.70 (0.31–1.58) 66 15 1.95 (0.92–4.11)
>0.47 15 58 0.73 (0.32–1.69) 60 18 1.49 (0.70–3.17)
Continuous, log-transformed 62 218 0.66 (0.26–1.67) 248 86 2.27 (0.96–5.41)
NOTE. Adjusted OR was adjusted for sex, age, race/ethnicity, and waist circumference. Quartiles were based on the population control groups.
aReported frequency of GERD symptoms as less than weekly.
bReported frequency of GERD symptoms as weekly or more than weekly.
cNot all population controls had GERD frequency data.
December 2015 Adiponectin and Barrett’s Esophagus 2261may protect against cancer. A study by Yildirim et al40
found lower levels of adiponectin among patients with
esophageal cancer (n ¼ 75 cases, 13 with adenocarci-
noma). Studies in cancer patients, however, have difﬁ-
culty excluding changes in adiponectin caused by the
cancer, such as alteration of diet, exercise, or metabolism.
Another study, which looked at the relationship between
adiponectin-receptor expression in esophageal adeno-
carcinoma cancer cells,41 found that greater amounts of
visceral fat were associated with greater expression of
the adiponectin receptor-2, independent of serum adi-
ponectin levels.41
The current results differ from 2 of 3 prior smaller
studies of Barrett’s esophagus. One study found lower
levels of low-molecular-weight serum adiponectin
among 112 Barrett’s esophagus patients vs GERD control
patients (third vs ﬁrst tertiles: OR, 0.33; 95% CI,
0.16–0.69) and no signiﬁcant associations for total or
high-molecular-weight adiponectin; the study did notinclude population controls.42 The second study found
lower total adiponectin levels among 177 Barrett’s
esophagus cases vs population controls (third vs ﬁrst
tertiles: OR, 0.56; 95% CI, 0.32–0.98).43 In contrast, the
third study found a nonsigniﬁcant trend for a positive
association between adiponectin and Barrett’s esoph-
agus, and signiﬁcant positive associations among white
males (fourth vs ﬁrst quartiles: OR, 3.27; 95% CI,
1.06–10.05).44 We cannot fully account for the differ-
ences between the prior studies and the current ﬁndings,
although some groups of patients without GERD in our
study did have inverse associations (Table 3) and some
of the other studies adjusted for smoking, GERD, and
hiatal hernia whereas we evaluated these primarily as
sources of interaction. All 3 prior studies had much
smaller sample sizes (decreasing the power to look for
interaction), slightly younger populations, and some had
fewer smokers in the control groups.41–44 Similar to
the current study, Thompson et al included only new
Figure 2. Adiponectin and
Barrett’s esophagus: cases
vs population controls.
Odds ratios (black circles)
and 95% conﬁdence in-
tervals (black bars) for adi-
ponectin quartiles adjusted
for sex, age, race/ethnicity,
and waist circumference.
Q, quartile.
2262 Almers et al Clinical Gastroenterology and Hepatology Vol. 13, No. 13diagnoses of Barrett’s esophagus, whereas Rubenstein
et al included both prevalent and new diagnoses and
reported somewhat lower mean adiponectin levels.42,43
The current results run counter to the general inverse
associations between adiponectin levels and obesity, and
the positive associations between abdominal obesity andFigure 3. Adiponectin and
Barrett’s esophagus: cases
vs GERD controls, strati-
ﬁed by smoking status and
sex. Stratiﬁed odds ratios
(black circles) and 95%
conﬁdence intervals (black
bars) for adiponectin log-
transformed concentra-
tions adjusted for age,
race/ethnicity, and waist
circumference.Barrett’s esophagus.5,45,46 However, prior positive asso-
ciations between abdominal obesity and Barrett’s
esophagus were observed mainly in comparisons with
population-based controls; no strong associations were
found among patients with GERD.5 Thus, given the
known associations between adiponectin and mucosal
December 2015 Adiponectin and Barrett’s Esophagus 2263healing, our current results represent a potential mech-
anism whereby only some patients with GERD develop
Barrett’s esophagus. The associations between abdom-
inal obesity and Barrett’s esophagus among population
controls may not be mediated strongly by adiponectin.
There were several strengths of the current study.
First, positive associations between adiponectin and
Barrett’s esophagus were found in both population
controls with self-reported GERD symptoms and patients
with physician-assigned GERD diagnoses. Second, our
analyses showed the expected associations between
adiponectin levels and sex, age, and BMI; this also makes
bias in the laboratory or with patient sampling less likely.
Third, we studied a large group of patients with a new
diagnosis of Barrett’s esophagus within a community-
based population, thereby minimizing selection bias
found in persons with prevalent Barrett’s esophagus.
Fourth, the number of cases was large,43 providing
greater power to evaluate interactions. Fifth, the 2 con-
trol groups allowed a separate evaluation of why only
some GERD patients develop Barrett’s esophagus. Sixth,
the data were of high quality, with validated question-
naires, detailed anthropometric measurements, direct
review of the endoscopy reports, and manual pathology
slide review.
The analyses had several potential limitations. First,
case-control studies cannot establish cause and effect;
adiponectin levels may differ without it, causing Barrett’s
esophagus.19 We cannot exclude incomplete control of
confounding. Second, we did not measure the adipo-
nectin levels at exactly the time the Barrett’s esophagus
developed, given that time is unknown. Fourth, low- and
medium-molecular-weight adiponectin were calculated
through subtraction of measured high-molecular-weight
adiponectin. Although the low- and medium-molecular-
weight forms of adiponectin together are the predomi-
nant forms in the circulation,47 high-molecular-weight
adiponectin appears to be the most bioactive form in
terms of regulating glucose homeostasis and insulin
sensitivity.10 The ﬁnding of a borderline stronger asso-
ciation between adiponectin and Barrett’s esophagus
among women vs men is interesting given that women
are at lower risk than men for this condition. Although
adiponectin levels are known to differ between men and
women, the interaction term was of marginal statistical
signiﬁcance (P ¼ .10) and there may be sex-speciﬁc
differences in its biological activities.
In summary, in a community-based population, there
was an association between increasing levels of serum
adiponectin multimers and a new diagnosis of Barrett’s
esophagus among patients with GERD. This association
was stronger among smokers, and among persons with
more frequent GERD. These results suggest a potential
for a direct mechanistic role for adiponectin in the
process of mucosal healing that may cause Barrett’s
esophagus, although it also is possible that circulating
adiponectin concentrations are a marker for another
process, such as systemic inﬂammation related toBarrett’s esophagus. Although the results run counter to
the expected direction of obesity’s general associations
with Barrett’s esophagus (and with adiponectin levels),
they represent one of the ﬁrst potential biological risk
factors identiﬁed for why only some patients with GERD
and smoking develop Barrett’s esophagus.
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Supplementary Table 1. Effects of Adipokines on Barrett’s Esophagus: Stratiﬁed by Never, Ever, Former, and Current Smokers for Cases Versus GERD Controls
Never smoker Ever smoker Former smoker Current smoker
Cases/
controls, n
Adjusted
OR 95% CI
Cases/
controls, n
Adjusted
OR 95% CI
Cases/
controls, n Adjusted OR 95% CI
Cases/
controls, n
Adjusted
OR 95% CI
N 217 361 297 64
Total adiponectin
Interaction term 0.247 (never
vs ever)
0.161 (former
vs current)
Quartiles mg/mL
<7.35 32/29 Ref 48/52 Ref 42/43 Ref 6/9 Ref
7.36–10.55 18/41 0.41 0.19–0.87 44/47 1.16 0.65–2.07 37.41 1.05 0.56–1.97 7/6 2.65 0.51–13.77
10.56–15.41 25/35 0.65 0.31–1.38 57/40 2.05 1.13–3.73 42/32 1.85 0.95–3.60 15/8 4.52 0.99–20.59
>15.46 28/20 1.40 0.57–3.44 57/44 2.34 1.24–4.41 44/36 2.13 1.06–4.28 13.8 4.59 0.79–26.56
Continuous, log-transformed 1.30 0.74–2.27 1.83 1.20–2.78 1.72 1.08–2.74 3.03 0.96–9.60
Adiponectin high MW
Interaction term 0.349 (never
vs ever)
0.114 (former
vs current)
Quartiles mg/mL
<1.46 30/34 Ref 52/55 Ref 46/45 Ref 6/10 Ref
1.46–2.53 24/36 0.80 0.38–1.66 49/41 1.47 0.82–2.62 40/35 1.31 0.70–2.46 9/6 3.54 0.71–17.62
2.54–4.00 19/30 0.69 0.31–1.54 50/36 1.89 1.03–3.46 36/30 1.59 0.81–3.12 14/6 5.26 1.15–24.09
>4.02 30/25 1.38 0.58–3.28 55/51 1.78 0.96–3.30 43/42 1.61 0.82–3.16 12/9 3.29 0.57–19.20
Continuous, log-transformed 1.06 0.71–1.58 1.46 1.09–1.97 1.39 1.01–1.92 2.22 0.96–5.14
Adiponectin low þ medium MW
Interaction term 0.167 (never
vs ever)
0.300 (former
vs current)
Quartiles mg/mL
<2.75 32/33 Ref 40/54 Ref 34/45 Ref 6/9 Ref
2.75–3.80 24/35 0.69 0.33–1.44 54/41 1.97 1.09–3.57 42/34 1.87 0.97–3.60 12/7 2.80 0.65–12.03
3.80–5.07 16/36 0.50 0.23–1.09 52/41 2.05 1.13–3.73 44/34 2.09 1.09–4.03 8/7 2.18 0.44–10.71
>5.07 31/21 1.56 0.68–3.55 60/47 2.62 1.41–4.89 45/39 2.40 1.20–4.78 15/8 4.32 0.88–21.15
Continuous, log-transformed 1.43 0.76–2.69 2.11 1.27–3.49 2.00 1.14–3.50 3.30 0.85–12.85
Adiponectin ratio high MW/total
Interaction term 0.064 (never
vs ever)
0.244 (former
vs current)
Quartiles
<0.32 30/26 Ref 55/41 Ref 51/35 Ref 4/6 Ref
0.32–0.39 21/38 0.40 0.18–0.88 46/55 0.68 0.38–1.22 34/43 0.61 0.32–1.15 12/12 1.98 0.39–10.04
0.39–0.47 28/30 0.63 0.28–1.43 54/40 1.12 0.61–2.05 42/31 1.05 0.54–2.02 12/9 2.09 0.36–12.16
>0.47 24/31 0.52 0.22–1.21 51/47 1.05 0.56–1.94 38/43 0.82 0.42–1.61 13/4 5.03 0.81–31.16
Continuous, log-transformed 0.66 0.25–1.71 1.64 0.80–3.36 1.46 0.68–3.13 4.62 0.50–42.89
NOTE. Adjusted OR was adjusted for sex, age, race/ethnicity and waist circumference. Quartiles were based on the population control groups.
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Supplementary Table 2. Effects of Adipokines on Barrett’s Esophagus: Stratiﬁed by Sex for Cases Versus GERD Controls
Males Women
Quartiles
N Cases/
controls, n
Adjusted
OR 95% CI Quartiles
N Cases/
controls, n
Adjusted
OR 95% CI
Total adiponectin
Interaction term 0.104
Quartiles mg/mL
1 <6.57 55/53 Ref <8.88 20/24 Ref
2 6.57–8.80 44/53 0.76 0.45–1.29 8.90–12.72 12/24 0.86 0.36–2.07
3 8.82–12.90 57/53 1.17 0.66–2.05 12.73–18.22 19/24 1.65 0.69–3.93
4 >12.90 71/53 1.56 0.89–2.74 >18.37 32/24 2.96 1.10–7.97
Continuous, log-transformed 1.50 1.02–2.22 2.27 1.15–4.47
Adiponectin high MW
Interaction term 0.230
Quartiles mg/mL
1 <1.25 54/53 Ref <1.96 18/24 Ref
2 1.26–1.96 57/53 0.97 0.57–1.64 1.96–3.12 15/24 0.78 0.32–1.89
3 1.96–3.31 49/53 1.46 0.83–2.56 3.12–4.87 17/24 1.40 0.57–3.44
4 >3.31 67/53 1.42 0.79–2.53 >4.87 33/24 2.67 1.02–7.00
Continuous, log-transformed 1.21 0.92–1.59 1.78 1.10–2.89
Adiponectin low þ medium MW
Interaction term 0.062
Quartiles mg/mL
1 <2.55 53/53 Ref <3.19 17/24 Ref
2 3.57–3.28 45/53 0.87 0.50–1.51 3.20–4.33 20/24 0.99 0.43–2.28
3 3.29–4.41 51/53 1.09 0.63–1.88 4.34–5.78 18/24 1.03 0.45–2.37
4 >4.42 78/53 2.20 1.24–3.92 >5.80 28/24 2.02 0.82–4.94
Continuous, log-transformed 1.78 1.13–2.80 2.23 1.00–4.97
Adiponectin ratio high MW/total
Interaction term 0.371
Quartiles
1 <0.32 75/53 Ref <0.35 19/24 Ref
2 0.32–0.37 33/53 0.74 0.43–1.27 0.35–4.20 20/24 1.12 0.46–2.74
3 0.37–0.46 72/53 1.13 0.64–2.00 4.20–0.49 16/24 0.95 0.40–2.28
4 >0.46 47/53 0.75 0.41–1.35 >0.49 28/24 1.73 0.73–4.14
Continuous, log-transformed 0.93 0.49–1.78 2.65 0.81–8.59
NOTE. Adjusted OR was adjusted for sex, age, race/ethnicity, and waist circumference. Quartiles were based on the population control groups.
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Supplementary Table 3. Associations of Adipokines on Barrett’s Esophagus: Stratiﬁed by BMI Category for Cases Versus Population Controls
Quartile
range
Normal BMI (18.5–24.9) Overweight BMI (25–29.0) Obese BMI (>30)
Cases/controls, n
Adjusted
OR 95% CI
Cases/
controls, n Adjusted OR 95% CI
Cases/
controls, n Adjusted OR 95% CI
Total adiponectin
Interaction term 0.73 0.82 0.95
Quartiles mg/mL
1 <7.35 4/6 35/33 42/38
2 7.36–10.55 6/19 0.38 0.07–1.92 28/25 1.13 0.54–2.35 28/32 0.82 0.41–1.64
3 10.56–15.41 16/12 1.81 0.39–8.40 34/34 0.96 0.48–1.93 32/30 1.04 0.52–2.07
4 >12.46 34/31 1.43 0.33–6.25 27/24 1.17 0.53–2.61 22/20 1.37 0.60–3.11
Continuous,
log-transformed
60/68 2.22 0.98–5.04 124/116 1.32 0.76–2.30 124/120 1.15 0.68–1.94
Adiponectin high MW
Interaction term 0.89 0.46 0.99
Quartiles mg/mL
1 <1.46 4/5 33/31 47/41
2 1.46–2.53 8/18 0.51 0.10–2.62 36/27 1.28 0.63–2.61 30/30 0.91 0.46–1.78
3 2.54–4.00 15/13 1.46 0.30–7.12 28/33 0.84 0.41–1.73 24/31 0.74 0.37–1.50
4 >4.02 33/32 1.23 0.27–5.56 27/25 1.12 0.50–2.51 23/18 1.60 0.69–3.71
Continuous,
log-transformed
60/68 1.63 0.90–2.96 124/116 1.08 0.74–1.58 124/120 1.18 0.82–1.71
Adiponectin low þ medium MW
Interaction term 0.08 0.13 0.82
Quartiles mg/mL
1 <2.75 4/10 29/32 37/35
2 2.75–3.80 9/14 1.91 0.43–8.45 35/29 1.38 0.67–2.84 35/33 1.04 0.52–2.07
3 3.80–5.07 15/16 2.86 0.69–11.84 30/31 1.07 0.51–2.25 25/29 0.93 0.44–1.92
4 >5.07 32/28 3.92 0.99–15.57 30/24 1.50 0.68–3.28 27/23 1.38 0.63–3.02
Continuous,
log-transformed
60/68 2.83 1.06–7.57 124/116 1.46 0.77–2.74 124/120 1.12 0.62–2.05
Adiponectin ratio high MW/total
Interaction term 0.04 0.27 0.17
Quartiles
1 <0.32 5/8 41/29 42/39
2 0.32–0.39 10/12 1.41 0.32–6.21 25/32 0.52 0.25–1.08 33/32 0.95 0.48–1.88
3 0.39–0.47 17/24 1.11 0.28–4.38 34/26 1.03 0.50–2.14 29/27 1.08 0.53–2.22
4 >0.47 28/24 1.74 0.44–6.86 24/29 0.63 0.30–1.33 20/22 0.97 0.44–2.16
Continuous,
log-transformed
60/68 1.64 0.33–8.14 124/116 0.78 0.34–1.82 124/120 1.71 0.74–3.93
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